Seres Therapeutics Inc. (MCRB) Downgraded by Zacks Investment Research to Sell
Seres Therapeutics Inc. (NASDAQ:MCRB) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday.
According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Several other brokerages also recently commented on MCRB. HC Wainwright assumed coverage on shares of Seres Therapeutics in a research report on Friday, July 29th. They set a “buy” rating and a $50.00 price objective on the stock. Cowen and Company restated a “buy” rating on shares of Seres Therapeutics in a research note on Tuesday, July 19th. Leerink Swann restated a “buy” rating and set a $43.00 target price on shares of Seres Therapeutics in a research note on Thursday, July 14th. FBR & Co restated a “buy” rating on shares of Seres Therapeutics in a research note on Friday, July 8th. Finally, Bank of America Corp. cut shares of Seres Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. Seres Therapeutics has an average rating of “Buy” and a consensus target price of $31.57.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/seres-therapeutics-inc-mcrb-downgraded-by-zacks-investment-research-to-sell.html
Seres Therapeutics (NASDAQ:MCRB) opened at 11.425 on Wednesday. The company’s market capitalization is $460.13 million. The firm has a 50 day moving average of $11.82 and a 200-day moving average of $22.90. Seres Therapeutics has a 1-year low of $8.05 and a 1-year high of $44.51.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by $0.24. The company had revenue of $3 million for the quarter, compared to the consensus estimate of $4.20 million. During the same quarter last year, the business earned ($1.45) earnings per share. The business’s revenue was up NaN% compared to the same quarter last year. On average, equities research analysts anticipate that Seres Therapeutics will post ($2.33) earnings per share for the current fiscal year.
In other news, insider John G. Aunins sold 9,390 shares of the stock in a transaction that occurred on Monday, August 29th. The shares were sold at an average price of $10.87, for a total value of $102,069.30. Following the transaction, the insider now owns 192,125 shares in the company, valued at approximately $2,088,398.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michele Trucksis sold 38,064 shares of the stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $35.14, for a total transaction of $1,337,568.96. Following the completion of the transaction, the insider now owns 38,064 shares in the company, valued at approximately $1,337,568.96. The disclosure for this sale can be found here. 41.90% of the stock is currently owned by insiders.
Several institutional investors have recently modified their holdings of the company. Birchview Capital LP acquired a new position in shares of Seres Therapeutics during the second quarter valued at $145,000. Pacad Investment Ltd. acquired a new position in shares of Seres Therapeutics during the second quarter valued at $198,000. First Mercantile Trust Co. acquired a new position in shares of Seres Therapeutics during the second quarter valued at $229,000. GSA Capital Partners LLP acquired a new position in shares of Seres Therapeutics during the second quarter valued at $273,000. Finally, American International Group Inc. boosted its position in shares of Seres Therapeutics by 106.4% in the second quarter. American International Group Inc. now owns 10,262 shares of the company’s stock valued at $298,000 after buying an additional 5,290 shares during the period. Hedge funds and other institutional investors own 78.28% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.